Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial
Kolon TissueGene’s knee osteoarthritis cell and gene therapy, TG-C, has failed to achieve statistical significance on its primary endpoints in its...
Search results for "U.S. Phase 3 clinical trial"
MediPost Begins Pivotal U.S. Phase 3 Trial for Regenerative Knee Therapy Cartistem
South Korean biotechnology company MediPost has entered full-scale Phase 3 clinical testing in the United States for its landmark knee osteoarthritis...
Can Daraxonrasib Reshape Pancreatic Cancer Care? Experts Weigh Promise and Limits
Pancreatic cancer remains one of the most formidable malignancies. Because early-stage disease rarely produces distinct...
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal
Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche...
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are...
Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27
Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's...
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...